Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Recently, the FDA expanded treatment indications for Gavreto (pralsetinib). According to MedPage Today, the drug was previously indicated for the treatment of patients with lung cancers with RET gene fusions. Now, this…
A recent article in BioSpace reported that Blueprint Medicines Corp. has submitted a New Drug Application (NDA) to the FDA for the investigational drug pralsetinib with an action date…
A recent BioSpace press release shares some exciting news for patients with non-small cell lung cancer, medullary thyroid cancer, and other thyroid cancers caused by RET gene mutations. Retevmo (selpercatinib) is the…
According to a story from The ASCO Post, the drug cabozantinib (marketed as Cometriq) was first approved by the US Food and Drug Administration (FDA) as a treatment for metastatic…
According to a story from Medscape, a recent study is highlighting the fact that many thyroid cancer survivors are still worried about cancer-related problems years after the conclusion of treatment.…
According to a press release from BeiGene, the Company and SpringWorks Therapeutics have launched MapKure, LLC — a new, jointly-operated venture owned by both partners. MapKure was founded to develop…
A recent article published in online CANCER NETWORK reports findings that indicate children who have survived Hodgkin lymphoma (HL) may develop solid tumors in later years. These findings will have…
According to a story from nbcwashington.com, Nikki Ferraro was diagnosed with a rare type of thyroid cancer when she was just seventeen years old. While she was able to survive…
According to a story from BBC, it is becoming increasingly clear that a lot of the common phrasing and language that we use to talk about cancer and cancer patients…
Emily Sadler is only 15. In March of 2017 she was diagnosed with thyroid cancer. This came as a huge shock to herself and loved ones, especially because thyroid cancer…
According to a story from Global Knock, nine year old Ashton Leeds has been living an active life again lately, but a year ago, things were not looking up for…
According to a story from ABC News, the FDA has recently approved Bayer and Loxo Oncology's drug Vitrakvi (larotrectinib) for the treatment of certain forms of solid-tumor cancers (like thyroid…
On November 26, 2018, a new drug was given accelerated approval by the FDA. Not only that, but it was granted orphan drug designation and breakthrough therapy designation. The drug…
Loxo Oncology has shared interim clinical data from an ongoing study of the drug LOXO-292. The study, a Phase 1/2 clinical trial, involves patients with RET-mutant medullary thyroid cancer, as…
The United States FDA has awarded Breakthrough Therapy Designation to a drug called LOXO-292 for the treatment of RET-altered non-small cell lung cancer and thyroid cancer, in patients who meet…
According to The Guardian, some researchers believe that the term "cancer" should be omitted from some medical diagnoses. Among these diagnoses include those for small thyroid cancer, low and intermediate…
According to a story from SFGate, many survivors of childhood cancers are plagued with financial burdens for the rest of their lives. This is because treatment of childhood cancer can…
According to a story from World Lifestyle, Emmy and Jake were high school sweethearts, destined for love. Indeed, even after years apart, the two found themselves together again after graduating…
According to a report by The Herald Scotland Online, a landmark study recently reveled flight crew to be exposed to greater than average risk of thyroid cancer. Surprisingly, the results…
According to a story from WebMD, a recent study concludes that the rates of diagnosis for thyroid cancer have been steadily increasing recently, and that it is over treated in…
According to a report by The Herald Scotland Online, a landmark study recently revealed that flight crews are exposed to greater risk than the average citizen. Surprisingly, the results have…
According to a story from Reuters, the cancer drug developer Loxo Oncology recently released the latest results from the trial testing its investigational therapy LOXO-292. Preliminary results released about a…
Loxo Oncology has announced that the US Food and Drug Administration (FDA) has granted the drug larotrectinib Priority Review, and accepted a New Drug Application (NDA) for it. These applications…
According to Timesunion, 10 patients in New York were diagnosed with the extremely rare eye cancer called vitreoretinal lymphoma. Since all of these diagnoses happened within four years of patients…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
